Survodutide for Heart Health: What the Evidence Shows
What human and animal studies show about Survodutide for heart health, how strong that evidence is, and what is still unproven.
- Strongest evidence
- None graded
- no study with an outcome for heart health (PubMed search, 2 Oct 2026)
- Human studies
- None found
- with an outcome for heart health, in our evidence file (PubMed search, 2 Oct 2026)
- Animal studies
- None found
- with an outcome for heart health, in our evidence file (PubMed search, 2 Oct 2026)
- Studies we summarised
- 1
- with an outcome for heart health
Evidence for heart health
Each row is an outcome related to heart health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Cholesterol, triglycerides and blood pressure | Modest reductions were noted in total cholesterol, triglycerides and blood pressure (no figures in the abstract). | Meta-analysisn = 1272 | Diabetes, obesity & metabolism 2025, PMID 40922121 |
Survodutide and heart health are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
Heart disease, and what the survodutide trials registered
MedlinePlus calls coronary artery disease the most common type of heart disease, caused by plaque building up in arteries that feed the heart muscle.[2]
The phase 2 obesity trial registered systolic blood pressure change to week 46 as a secondary outcome.[3]
The first phase 3 trial registered systolic blood pressure change at week 76 as a secondary outcome.[4]
The phase 3 trial in people with diabetes registered the same systolic blood pressure measure at week 76.[5]
What pooled data say about pressure and lipids
A pooled analysis reported modest reductions in total cholesterol, triglycerides and blood pressure, as well as significant falls in BMI.[1]
Heart-related reports and gaps
No cardiovascular-event outcome appears among the registered endpoints cited for these three survodutide trials: they list blood pressure (3 of 3), but none lists heart attack or heart failure counts.
Calculated from registry records NCT04667377, NCT06066515, NCT06066528; blood pressure endpoints found 3; heart event endpoints found 0. Formula: count of cached registry outcome lists naming the item
Other peptides people research for heart health
All peptides for heart health, comparedCommon questions
Does Survodutide help with heart health?
None of the studies we summarised for Survodutide (PubMed search, 2 Oct 2026) measured an outcome for heart health. Treat claims that it helps with heart health as unproven.
Is Survodutide approved for heart health?
No. Survodutide is not FDA approved for any use, including heart health.
What is the best peptide for heart health?
There is no single answer. Our heart health overview compares each candidate by evidence grade and legal status rather than by popularity.
Is survodutide good for the heart?
The cached evidence reports blood pressure and lipid changes of a modest size, not heart-attack or heart-failure outcomes.[1]
Does survodutide lower blood pressure?
The registered phase 3 records list systolic blood pressure change at week 76, but the cached records carry no posted results.[5]
More on Survodutide
Sources
- 1Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.Diabetes, obesity & metabolism · 2025PMID 40922121Accessed 2 Oct 2026
- 2Official web pageOfficial web page · web page
- 3A Phase II, Randomized, Double Blind, Parallel Group,46 Weeks Dose-finding Study of BI 456906 Administered Once Weekly Subcutaneously Compared With Placebo in Patients With Obesity or OverweightClinicalTrials.gov (U.S. National Library of Medicine) · 2020clinicaltrials.govAccessed 2 Oct 2026
- 4A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity Without Type 2 DiabetesClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
- 5A Phase 3, Randomised, Double-blind, Parallel-group, 76-week, Efficacy and Safety Study of BI 456906 Administered Subcutaneously Compared With Placebo in Participants With Overweight or Obesity and Type 2 Diabetes MellitusClinicalTrials.gov (U.S. National Library of Medicine) · 2023clinicaltrials.govAccessed 2 Oct 2026
Found an error? Report a correction.